Table 1.
Demographic and Biochemical Characteristics of Study Groups
| Group | Normotensive | HT without PAF | HT with PAF |
|---|---|---|---|
| Number of subjects | 30 | 27 | 30 |
| Men/women | 16/14 | 15/12 | 17/13 |
| Age (years) | 53 ± 5 | 52 ± 7 | 53 ± 9 |
| Systolic blood pressure (mmHg) | 120 ± 6 | 153 ± 8* | 154 ± 11* |
| Diastolic blood pressure (mmHg) | 85 ± 6 | 86.4 ± 7 | 85.3 ± 6 |
| Duration of hypertension (year) | 4.3 ± 1.1 | 7.4 ± 3.1 † | |
| Medications (%) | |||
| ACEI/ARB | 4(%15) | 5(%16) | |
| Beta-blockers | 6(%22) | 6(%20) | |
| Calcium-blockers | 7(%26) | 8(%26) | |
| Diuretics | 10(%37) | 11(%36) | |
| Heart rate (bpm) | 77 ± 5 | 74 ± 3 | 75 ± 5 |
| BMI (kg/m2) | 21.3 ± 2.8 | 23.2 ± 2.4 | 23.4 ± 3.3 |
| Glucose (mg/dL) | 93.4 ± 7.5 | 95.2 ± 3.1 | 96.1 ± 2.9 |
| Total cholesterol (mg/dL) | 189.6 ± 17.2 | 182.4 ± 6.0 | 184.3 ± 8.4 |
| HDL cholesterol (mg/dL) | 45.8 ± 10.2 | 43.8 ± 12.0 | 46.2 ± 11.3 |
| LDL cholesterol (mg/dL) | 116.4 ± 11.3 | 115 ± 11.2 | 118.1 ± 10.5 |
| Triglyceride (mg/dL) | 138.0 ± 37.5 | 134.3 ± 29.0 | 132.8 ± 25.3 |
*
p < 0.05; compared with normotensive subjects
†
p<0.01; compared with hypertensive patients without PAF. HT: Hypertension; PAF: Paroxysmal atrial fibrillation; ACEI: Angiotensin converting enzyme inhibitor; ARB: Angiotensin II receptor blocker; BMI: Body mass index.